How can we cure

serious diseases for good

Pharma

Project in a nutshell

MVP. Since 2024, our client has been advancing groundbreaking gene therapies to cure severe diseases. blu BEYOND supported the development of an MVP that for the first time brought together key departments, automated workflows, and harmonized existing systems.

The Customer Need

More than just tech. As an innovative pharmaceutical company, the client knew that before jumping into solutions, the business capabilities had to be clearly defined. At project kick-off, our experts stepped into new roles to co-develop a Business Capability Map for the Gene Therapy Unit through deep engagement with staff. Together, we mapped out the functional needs for core areas such as Process Development, Clinical Manufacturing, Lab Analytics, and Data Analysis – always aligned with technical requirements and GMP regulations (Good Manufacturing Practice).

Challenges & Extra Miles

Information & communication. Anyone who’s worked in a corporate setting knows: getting access to the right information can be tough—especially mid-operations. In high-profile projects like this one, key players are often only sporadically available. Add to that the integration of legacy systems and diverse teams with varying goals - it makes communication and planning complex. At this client, each department also had its own IT experts. This required more collaboration than usual, and demanded operational structures based on business processes rather than organizational hierarchies.

Digital Strategy

Integration drives innovation. Based on the Capability Map, we created new teams. Since system harmonization was key to any innovation, we formed two integration teams: one for internal systems, another for enterprise systems. All crucial steps toward a well-integrated MVP aligned with future downstream processes.
Other strategic building blocks:
Fit/Gap Analysis: Reviewed all existing systems and identified what new tools would be needed to deliver the required business capabilities.
SAFe-inspired approach: To solve organizational challenges within growing teams, we suggested a scaled agile framework (SAFe-like). The rapid growth of the teams and the program itself validated our approach—enabling stability, clarity, and eventual scaling.

Innovation

MVP for the Gene Therapy Unit. Our approach to MVPs always starts with value first. Here, we developed an end-to-end solution automating processes and equipment control services. Integration of legacy data and harmonization of the system landscape were crucial for long-term success.

Technical Solution

Automation accelerates gene therapy. The MVP went live in 2024—and it's working. Since then, we’ve steadily increased automation levels, improved data structuring, and enabled smarter data usage. This means more time for scientists, lower costs, and over time, a powerful data pool. With advanced data analytics—from reporting to AI—expensive lab experiments can be reduced, accelerating the path to market for new therapies.

Big

Wins

A project bigger than ourselves. Gene therapy works at the cellular level—targeting disease at the source, in the genetic code. Unlike conventional approaches, this reduces side effects and offers the chance to cure, not just treat. Being part of this project has been deeply meaningful for our team. It’s not just another MVP—it’s a mission that reinforces why we do what we do.

Small Victories

1.

A new culture of collaboration We brought together people and teams who had never worked together before—and now, they do. We also introduced blu BEYOND’s values and ways of working in to the client organization.
2.

Remote collaboration kept things moving This project ran through the pandemic—but you wouldn’t know it. We’ve always worked remotely and equitably across global teams, so there was no collaboration breakdown. No COVID dip in momentum here.

MVP for innovative

Gene Therapy

Content

Legal

We are blu